A PYMNTS Company

EU Watchdog Set To Accept Aspen Concessions

By  |  February 3, 2021

EU antitrust regulators are set to accept South African pharmaceutical company Aspen’s concessions aimed at ending a three-year long investigation that could lead to a hefty fine, two people familiar with the matter said.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     Aspen last year offered to cut prices by an average of 73% for six off-patent cancer drugs after the European Commission voiced concerns that it may have charged excessive prices for drugs used for cancer patients.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.